Novo Nordisk (NVO-NYSE, $57.57 US). Does an Oral GLP-1 Mega-Blockbuster Await in the Wings at Novo?

Novo Nordisk, the world’s biggest insulin maker, has for years kept away from the acquisition strategy of Sanofi, Pfizer Inc. and other drugmakers, preferring to focus on internal research and development. That tack has paid off for Novo, the best-performing stock in the 20-member Bloomberg Europe Pharmaceutical Index over the past 10 years.

“Novo Nordisk expects to double production of its diabetes drugs over the next decade”.

Posted in Open Blog

Leave a Reply

Recent Comments